Alzheimer Disease Clinical Trial
— VAAPSOfficial title:
Association Between Cerebral Arterial Vascular Flow and Sleep Apnea in Neurodegenerative Alterations
Obstructive sleep apnea syndrome (OSAS) is a sleep-disordered breathing characterized by the
occurrence of repeated upper airway obstructions leading to airflow reduction (hypopnea) or
cessation (apnea). The apnea-hypopnea index (AHI) is the number of apneas and hypopneas per
hour of sleep. OSA patients often report cognitive complaints.
About 25% of the elderly population is affected by this syndrome with a drastic increase of
this rate among dementia patients. OSAS is considered to be an important risk factor for the
development of hypertension, heart disease and stroke.
Status | Recruiting |
Enrollment | 139 |
Est. completion date | January 1, 2022 |
Est. primary completion date | January 1, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 75 Years to 120 Years |
Eligibility |
Inclusion Criteria: 1. Elderly patients about or over 75 years 2. Any gender 3. Dementia Group: 3.1. MMSE (Mini Mental State Examination)> 15 3.2. Diagnosis of dementia established according to DSM-IV 3.3. Dementia of the Alzheimer type from NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) 4. Control Group: Preserved cognitive function corresponding to a normal MMSE score by the standards of Poitrenaud 5. Ability to understand and give consent freely (for demented subjects, a legal representative will be delegate) Exclusion Criteria: 1. Elderly patients under 75 years 2. Anyone with a classic contraindication to MRI 2.1 Major behavioral disorders that do not allow the realization of MRI in optimal conditions 2.2 Claustrophobia 2.3 Presence of foreign non-compliant material 2.4 Presence of intraocular metal body 3. Having a history of chest surgery or neurosurgical 4. Chronic respiratory failure 5. Suffering from dementia other than that associated with Alzheimer's disease 6. Patients with a handicap 7. Patients under legal protection |
Country | Name | City | State |
---|---|---|---|
France | CH Saint-Quentin | Saint-Quentin |
Lead Sponsor | Collaborator |
---|---|
Central Hospital Saint Quentin |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total arterial flowrate (measured by PC-MRI debit ml/Mn) | at day 1 after inclusion | ||
Secondary | sleep apnea measured by elderly polygraphy (Number of apneas / night) | at day 1 after inclusion up to 24 heures |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |